ArticleJornal brasileiro de nefrologia
The impact of bone histomorphometry, bone-related biomarkers, and FRAX® on fractures patients with predialysis CKD.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fragility fractures and risk factors in a peritoneal dialysis setting.Archives of osteoporosis · 2026Article
- Reply to the letter: will non-invasive methods replace bone biopsy in patients with chronic kidney disease?Jornal brasileiro de nefrologiaArticle
- Fractures in CKD predialysis: the role of bone biopsy, biomarkers, and FRAX®.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) patients are at increased risk of fracture. Whether the type of renal osteodystrophy (ROD) contributes to fracture risk is not currently established since bone biopsies are not frequently performed in clinical practice. We aimed to evaluate the association of ROD subtypes, bone biomarkers, and fracture risk assessed with the FRAX® tool with the occurrence of fractures in predialysis CKD patients.
methodsRetrospective study with patients followed between 2014-2023. Blood tests, including bone-related biomarkers (BRB), and bone biopsies were performed at the beginning of follow-up. Data from dual x-ray absorptiometry (DXA) scan and clinically evident fractures were obtained from medical registries. Radiographs of the thoracic/lumbar spine were evaluated to detect vertebral fractures, and the FRAX® index without bone mineral density (BMD) was calculated with the web-based tool.
resultsMedian follow-up time was 7.5 ± 3 years and 9.3% of the patients had a bone fracture, with an incidence of 12/1000 patient-year. Patients who had a fracture had higher phosphorus levels (4.1 mg/dL vs 3.5 mg/dL, p = 0.047). Histomorphometric subtypes and BRB were not associated with incidence of fractures nor with fracture risk assessed by FRAX®. There was a tendency for lower bone volume in the group with fractures (p = 0.057). FRAX® (without BMD), regardless of the inclusion of CKD as secondary osteoporosis, showed an overall good diagnostic accuracy for predicting fractures in predialysis CKD.
conclusionROD subtypes were not associated with incidence of fractures in these patients. The discriminative ability of FRAX in this population emphasizes its usefulness in CKD predialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.